 Vincristine
"Vincristine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
| Descriptor ID |
D014750
|
| MeSH Number(s) |
D03.132.436.681.827.817 D03.633.100.473.402.681.827.817
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vincristine".
Below are MeSH descriptors whose meaning is more specific than "Vincristine".
This graph shows the total number of publications written about "Vincristine" by people in this website by year, and whether "Vincristine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 1 | 1 | | 2006 | 0 | 2 | 2 | | 2009 | 1 | 1 | 2 | | 2010 | 0 | 4 | 4 | | 2011 | 1 | 3 | 4 | | 2012 | 0 | 2 | 2 | | 2014 | 0 | 5 | 5 | | 2015 | 0 | 3 | 3 | | 2016 | 1 | 3 | 4 | | 2017 | 0 | 5 | 5 | | 2018 | 2 | 2 | 4 | | 2019 | 1 | 4 | 5 | | 2020 | 1 | 3 | 4 | | 2021 | 1 | 6 | 7 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 6 | 6 | | 2024 | 2 | 3 | 5 | | 2025 | 1 | 2 | 3 | | 2026 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Vincristine" by people in Profiles.
-
Flerlage JE, Feraco AM, Zhou Y, Zheng Y, Liang J, Lucas JT, Friedmann AM, Weinstein HJ, Yock TI, Shulkin B, Kaste SC, Marks LJ, Ehrhardt MJ, Dixon SB, Howard S, de Alarcon P, Luna-Fineman S, Geddis A, Larsen EC, Marcus K, Billett AL, Donaldson SS, Hudson MM, Metzger ML, Krasin MJ, Link MP. Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08. Blood. 2026 Mar 19; 147(12):1289-1301.
-
Jamnick NA, Livingston PD, Gammon CJ, Weinzierl NM, Novinger LJ, Adams DJ, Bonetto A. Vincristine impairs musculoskeletal development in pediatric mice. BMC Cancer. 2025 Nov 18; 25(1):1782.
-
Hess B, Moskowitz A, Davis JA, Strati P, Sawalha Y, Bakos J, Sorrell M, Ferreira AC, Escribano-Serrat S, De Castro M, Brooks TR, Hill BT, Shah GL, Falade AS, Merryman R, Kamdar M, Ip A, Nachar V, Bennett JG, Lux N, Ahmed N, Hoffmann M, LaCasce A. Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R. Haematologica. 2026 Apr 01; 111(4):1389-1395.
-
Mondello P, Negaard B, Feldman AL, Link BK, Casulo C, Chihara D, Russler-Germain D, Romancik J, Gribbin C, Haddadi S, Mou E, Micallef IN, Johnston PB, Novak J, Wang Y, King RL, Novak AJ, Habermann TM, Martin P, Kahl B, Nowakowski GS, Nastoupil LJ, Cerhan JR, Flowers CR, Lossos IS, Burack RW, Maurer MJ, Ansell SM. Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts. Blood Cancer J. 2025 Aug 08; 15(1):134.
-
Allen J, Abbott D, Eskandar J, Bair SM, Haverkos B, Jasem J, Kamdar M, Major A. DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2025 Jan; 25(1):e26-e33.
-
Guièze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, Aurran T, Clavert A, de Guibert S, Michallet AS, Saad A, Drénou B, Quittet P, Hivert B, Laribi K, Gay J, Quinquenel A, Broseus J, Rouille V, Schwartz D, Magnin B, Lazarian G, Véronèse L, de Antonio M, Laurent C, Tournilhac O, Pereira B, Feugier P. Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial. Nat Commun. 2024 Aug 09; 15(1):6822.
-
Meyers PA, Federman N, Daw N, Anderson PM, Davis LE, Kim A, Macy ME, Pietrofeso A, Ratan R, Riedel RF, Trucco M, Breitmeyer JB, Toretsky JA, Ludwig JA. Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. J Clin Oncol. 2024 Nov; 42(31):3725-3734.
-
Gupta AA, Xue W, Harrison DJ, Hawkins DS, Dasgupta R, Wolden S, Shulkin B, Qumseya A, Routh JC, MacDonald T, Feinberg S, Crompton B, Rudzinski ER, Arnold M, Venkatramani R. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Lancet Oncol. 2024 07; 25(7):912-921.
-
Iguchi N, Teimouri A, Wilcox DT, Malykhina AP, Cost NG. Lower urinary dysfunction as a long-term effect of childhood vincristine treatment, with potential influences by sex and dose. Sci Rep. 2024 07 01; 14(1):15049.
-
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M. Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncol. 2024; 20(21):1455-1465.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|